FDA reviewing Amgen data on anemia drugs
2:28 PM Fri, Jan 04, 2008 | Permalink
Email this author | Email this entry |
 |
Projo Biz Blog |
|
« Providence Chamber tries to revive city's economy |
Main
| Paint companies seek overturn of cleanup plan »
The Food and Drug Administration is reviewing new data submitted by Amgen Inc. related to its troubled anemia drugs Aranesp and Epogen. The Wall Street Journal reported today that the new data "provide further evidence of the risks of anemia drugs." "The FDA said the studies show that patients with breast or advanced cervical cancers who received ESAs to treat anemia caused by chemotherapy died sooner or had more-rapid tumor growth than similar patients who didn't receive the anemia drugs," according to The Wall Street Journal. Safety concerns have caused sales of the drugs to plunge, prompting Amgen to cut spending. That effort resulted in the layoff, last fall, of 300 Amgen employees in Rhode Island. 
|
New comments
New photos
Authors
New posts
Projo blogs
Archives
Leave a comment